Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.5 USD | -0.83% | +9.63% | -9.70% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.93 times its estimated earnings per share for the ongoing year.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.70% | 15.33B | C+ | ||
+17.59% | 66.6B | A- | ||
+0.84% | 48.75B | A- | ||
+17.11% | 41.45B | B+ | ||
+22.26% | 26.74B | A- | ||
+11.45% | 19.55B | C+ | ||
+5.08% | 18.21B | B+ | ||
-21.31% | 16.02B | A- | ||
+4.28% | 15.62B | B+ | ||
-20.79% | 13.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALB Stock
- Ratings Albemarle Corporation